Co-Diagnostics Secures Key Japanese Patent for PCR Platform
Event summary
- Co-Diagnostics received Japanese Patent No. 7797537 for its Co-Dx PCR platform technologies on March 12, 2026.
- The patent includes 34 claims and was filed under the Patent Cooperation Treaty (PCT).
- This follows a similar patent granted by the Australian Patent Office in 2025.
- The Co-Dx PCR platform is designed for point-of-care molecular diagnostics but is not yet available for sale pending regulatory approvals.
The big picture
The grant of this comprehensive patent by the Japan Patent Office, known for its rigorous review process, underscores the uniqueness of Co-Diagnostics' Co-Dx PCR platform. This intellectual property fortification supports the company's strategy to expand into global markets with affordable, high-performance point-of-care PCR testing solutions. The patent also enhances Co-Diagnostics' ability to pursue commercial opportunities and regulatory initiatives in Japan, a key market for advanced diagnostic technologies.
What we're watching
- Regulatory Approvals
- The pace at which Co-Diagnostics secures FDA and other regulatory approvals for its Co-Dx PCR platform will determine its commercial viability.
- Market Expansion
- Whether Co-Diagnostics can leverage this patent to strengthen its position in the Japanese market and attract local partnerships.
- Competitive Positioning
- How this patent strengthens Co-Diagnostics' competitive edge against other molecular diagnostics companies in key international markets.
Related topics